Intellia Therapeutics NTLA Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Intellia Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Intellia Therapeutics's cash ratio?
- Intellia Therapeutics (NTLA) reported cash ratio of 1.8× in Q1 2026.
- How has Intellia Therapeutics's cash ratio changed year-over-year?
- Intellia Therapeutics's cash ratio increased by 56.4% year-over-year, from 1.1× to 1.8×.
- What is the long-term trend for Intellia Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Intellia Therapeutics's cash ratio has grown at a -9.7% compound annual growth rate (CAGR), from 2.5× to 1.5×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.